https://www.pharmaceutical-technology.com/data-insights/ibrance-pfizer-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-348885&utm_campaign=recommended-articles-pi
Ibrance is under clinical development by Pfizer and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
prostate canceribrancepfizermetastaticcastration
https://www.pharmaceutical-technology.com/data-insights/nuv-1511-nuvation-bio-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/
NUV-1511 is under clinical development by Nuvation Bio and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
nuvbiometastaticcastrationresistant
https://www.pharmaceutical-technology.com/data-insights/inkmune-inmune-bio-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/
INKmune is under clinical development by Inmune Bio and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
prostate cancerbiometastaticcastrationresistant
https://uroweb.org/education-events/urowebinar-new-treatment-options-in-mcrpc
In this recording, the panel of experts will provide you with key takeaways, the latest updates, and helpful insights on metastatic castration-resistant...
treatment optionscoursenewmcrpc
https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/
Botensilimab is under clinical development by Agenus and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
prostate canceragenusmetastaticcastrationresistant
https://www.mdpi.com/2072-6694/15/19/4809
Registrative trials recommended the use of upfront chemotherapy in high-volume metastatic prostate cancer. We reported survival outcomes of patients with...
high volumeoncologicaloutcomespatientsmcrpc
https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/
Avelumab is under clinical development by Merck and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
prostate canceravelumabmerckmetastaticcastration
https://www.ajmc.com/view/osteomimicry-may-contribute-to-uptake-of-radium223-within-bone-metastases-for-patients-with-mcrpc
Osteomimicry may contribute to the uptake of radium-223 within bone metastases and may subsequently enhance the therapeutic benefit of radium-223, according to...
osteomimicrymaycontributeuptakeradium